SCHEMBL24792596

SCHEMBL24792596

CC(C)(C)OC(=O)N1CC=C(c2cccc(COc3ccc(Cl)cc3Cl)c2)C1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MRGPRX4 Q96LA9 13/20 0.47
▸ KCNH2 Q12809 1/20 0.44
▸ ALDH1A1 P00352 3/20 0.43
▸ SMN1; SMN2 Q16637 3/20 0.43
▸ MAPT P10636 2/20 0.43
▸ HTT P42858 2/20 0.43
▸ HPGD P15428 2/20 0.43
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ MDM2 Q00987 1/20 0.43
▸ GPR55 Q9Y2T6 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TSHR P16473 1/20 0.43
▸ USP2 O75604 1/20 0.43
▸ GPR119 Q8TDV5 1/20 0.42
▸ GAA P10253 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24792024 0.82 MRGPRX4 (0.49) MRGPRX4HPGDTSHRUSP2GPR119
SCHEMBL24792595 0.80 PDK4 (0.46) GPR119
SCHEMBL30053574 0.79 PDK4 (0.44) GPR119
SCHEMBL24791728 0.79 MRGPRX4 (0.48) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT
SCHEMBL24791720 0.78 MRGPRX4 (0.51) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT
SCHEMBL30053308 0.77 MRGPRX4 (0.48) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT
SCHEMBL24792589 0.77 MRGPRX4 (0.48) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT
SCHEMBL22619074 0.76 PDK4 (0.48) GPR119
SCHEMBL24793021 0.75 PDE4B (0.50) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT
SCHEMBL24793022 0.75 PDE4B (0.50) MRGPRX4KCNH2ALDH1A1SMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4461355-A2 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-11-13 — — EP disclosed
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2024-08-08 — — US disclosed
EP-4334304-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE Carmot Therapeutics, Inc. (US) 2024-03-13 — — EP disclosed
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2022-12-15 — — US disclosed
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. 2022-12-15 — — US disclosed
WO-2022235717-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE CARMOT THERAPEUTICS, INC. (US) 2022-11-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220396569-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR MRGPRX4 131/4885KCNH2 1832/4885ALDH1A1 3087/4885
US-20240262811-A1 BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE GLP1R, GIPR, GCGR MRGPRX4 131/4885KCNH2 1832/4885ALDH1A1 3087/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback